Joe Blumenau, MD – FDA EIR, Aug 10, 2017

An FDA inspection of Joe Blumenau, MD, a clinical research site in Dallas, TX, was conducted from August 4-10, 2017. This high-priority assignment, falling under the Center for Drug Evaluation and Research's framework for Clinical Investigators, aimed to assess compliance with regulations governing clinical trials. While no FDA Form 483 was issued, the inspection identified significant discrepancies related to adverse event reporting and data management. The primary issues observed included a consistent pattern of untimely adverse event reporting, with adverse events often entered into the electronic system months after study visits or not reported to the sponsor at all. This was partly attributed to the site's delayed access to the Electronic Data Capture (EDC) system, which became available approximately two months into the study. Furthermore, the study protocol lacked specific timeframes for adverse event reporting to the sponsor, and there was noted confusion among staff regarding the accurate documentation of symptoms. The report also highlighted a perceived lack of monitoring oversight in identifying and prompting the reporting of missed or delayed adverse events. During a close-out meeting, these concerns were discussed with Dr. Blumenau and his team, emphasizing the need for clarification on adverse event reporting practices. The Agency will conduct a further review of the report for final classification.